Patents by Inventor Charles Zepp
Charles Zepp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110293701Abstract: The invention relates, at least in part, to compositions comprising populations of synthetic nanocarriers that comprise different sets of antigens as well as related methods.Type: ApplicationFiled: May 26, 2011Publication date: December 1, 2011Applicant: Selecta Biosciences, Inc.Inventors: Robert L. Bratzler, Lloyd Johnston, Grayson B. Lipford, Charles Zepp
-
Publication number: 20110293723Abstract: Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.Type: ApplicationFiled: May 26, 2011Publication date: December 1, 2011Applicant: Selecta Biosciences, Inc.Inventors: Robert L. Bratzler, Grayson B. Lipford, Lloyd Johnston, Charles Zepp
-
Publication number: 20110171248Abstract: Disclosed are compositions and related methods that involve a synthetic nanocarrier that includes at least one peptide obtained from Human papillomavirus L1 or L2 capsid protein; wherein the peptide is coupled to an external surface of the synthetic nanocarrier.Type: ApplicationFiled: January 7, 2011Publication date: July 14, 2011Applicant: Selecta Biosciences, Inc.Inventors: Lynnelle Ann McNamee Pittet, Yun Gao, Charles Zepp, Grayson B. Lipford
-
Patent number: 7963450Abstract: Systems and methods of providing a covert security marking for items such as documents, packaging, credit cards, and other valuable goods to combat the steady increase in forgery, counterfeiting, and other fraudulent activities is presented. A spectrally narrow, near infrared ink system serves as the basis of a covert security feature for items of value. Alternatively, or in combination, metal oxides having a substantially narrow absorption band and a maximum absorption wavelength of electromagnetic radiation in the near infrared range are also utilized.Type: GrantFiled: June 19, 2008Date of Patent: June 21, 2011Assignee: Spectra Systems CorporationInventors: Nabil M. Lawandy, Tim Driscoll, Jeff Conroy, William Goltsos, Charles Zepp
-
Publication number: 20110027217Abstract: This invention relates to compositions, and related compounds and methods, of conjugates of immunomodulatory agents and polymers or unit(s) thereof. The conjugates may be contained within synthetic nanocarriers, and the immunomodulatory agents may be released from the synthetic nanocarriers in a pH sensitive manner.Type: ApplicationFiled: May 26, 2010Publication date: February 3, 2011Applicant: SELECTA BIOSCIENCES, INC.Inventors: CHARLES ZEPP, GRAYSON B. LIPFORD, YUN GAO, LLOYD JOHNSTON, FEN-NI FU FU, MARK J. KEEGAN, SAM BALDWIN
-
Publication number: 20110020388Abstract: This invention relates to compositions, and related methods, of synthetic nanocarriers that target sites of action in cells, such as antigen presenting cells (APCs), and comprise immunomodulatory agents that dissociate from the synthetic nanocarriers in a pH sensitive manner. Also disclosed are compositions and methods relating to synthetic nanocarriers that encapsulate labile immunomodulatory agents that dissociate from the synthetic nanocarriers in a pH sensitive manner.Type: ApplicationFiled: May 26, 2010Publication date: January 27, 2011Applicant: Selecta Biosciences, Inc.Inventors: CHARLES ZEPP, Yun Gao, Mark J. Keegan, Sam Baldwin, Fen-ni Fu, Lloyd Johnston, Grayson B. Lipford
-
Publication number: 20100303850Abstract: This invention relates to compositions, and related methods, of synthetic nanocarriers that comprise immunomodulatory agents and antigens that are differentially released from the synthetic nanocarriers.Type: ApplicationFiled: May 26, 2010Publication date: December 2, 2010Applicant: Selecta Biosciences, Inc.Inventors: Grayson B. Lipford, Charles Zepp, Yun Gao, Mark J. Keegan, Sam Baldwin, Fen-ni Fu, Llyod Johnston
-
Publication number: 20090045617Abstract: Systems and methods of providing a covert security marking for items such as documents, packaging, credit cards, and other valuable goods to combat the steady increase in forgery, counterfeiting, and other fraudulent activities is presented. A spectrally narrow, near infrared ink system serves as the basis of a covert security feature for items of value. Alternatively, or in combination, metal oxides having a substantially narrow absorption band and a maximum absorption wavelength of electromagnetic radiation in the near infrared range are also utilized.Type: ApplicationFiled: June 19, 2008Publication date: February 19, 2009Inventors: Nabil M. Lawandy, Tim Driscoll, Jeff Conroy, William Goltsos, Charles Zepp
-
Patent number: 7410975Abstract: The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.Type: GrantFiled: June 18, 2004Date of Patent: August 12, 2008Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Grayson B. Lipford, Alexandra Forsbach, Charles Zepp
-
Publication number: 20070232622Abstract: The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.Type: ApplicationFiled: October 4, 2006Publication date: October 4, 2007Applicants: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Grayson Lipford, Alexandra Forsbach, Charles Zepp
-
Publication number: 20070060555Abstract: Compounds are disclosed of the formula in which R3 is C8 to C24 hydrocarbon or the residue of misoprostol. The compounds are useful for treating rhinitis and asthma, particularly by inhalation, and for treating inflammation, particularly by local or topical administration.Type: ApplicationFiled: November 14, 2006Publication date: March 15, 2007Applicant: Sepracor Inc.Inventors: Mark Currie, Steven Jones, Charles Zepp
-
Publication number: 20050119273Abstract: The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.Type: ApplicationFiled: June 18, 2004Publication date: June 2, 2005Applicants: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Grayson Lipford, Alexandra Forsbach, Charles Zepp
-
Publication number: 20050101534Abstract: Ototoxic side-effects have either limited the application of an important group of antibiotics, aminoglycoside antibiotics, or have added further burden to those who have to resort to platinum-containing antineoplastic agents to treat life-threatening tumors. The present invention discloses pharmaceutical compositions that prevent or treat the ototoxic side-effects of aminoglycoside antibiotics and platinum-containing antineoplastic agents. The otoprotective compositions disclosed herein can also be used to treat noise induced hearing loss.Type: ApplicationFiled: November 13, 2003Publication date: May 12, 2005Applicant: Sepracor, Inc.Inventors: Charles Zepp, Donald Heefner, Paul Rubin, Mark Currie
-
Publication number: 20050058800Abstract: Methods and apparatus are provided for making an optically readable media unreadable and tamper-resistant. A method is disclosed for making an optically readable media unreadable, as is a media that operates in accordance with the method. The method has steps of (a) providing the media with a readout surface layer that is non-flat (i.e., textured in some way, such as by embossing, scratching, depositing a non-planar layer or regions, such as droplets) and that inhibits optical readout of the media; (b) applying a coating layer to the non-flat surface layer to smooth the non-flat surface and to enable optical readout of the media; and, after an initiation of a readout period, (c) removing the coating layer so as to expose the non-flat readout surface layer, thereby inhibiting optical readout of the media. Preferably, the coating layer is substantially index matched to the readout surface layer.Type: ApplicationFiled: June 25, 2004Publication date: March 17, 2005Applicant: Flexplay Technologies, Inc.Inventors: Nabil Lawandy, Charles Zepp, Andrei Smuk, Marianne Krieg-Kowald
-
Patent number: 5422382Abstract: Substituted xanthene compounds are described which are capable of functioning as absorbers in high intensity light protective compositions and in materials used to prevent the transmission of high intensity light at selected wavelengths. Also described are high intensity light protective compositions containing an effective amount of a substituted xanthene compound and a polymeric compound and a material which prevents transmission of high intensity light at wavelengths between about 482 to about 556 nanometers. The material of this invention can be used to make protective eyewear, optical filters, shields for protecting a persons body from high intensity light, or shields for protecting components of an optical instrument from high intensity light.Type: GrantFiled: June 16, 1992Date of Patent: June 6, 1995Assignee: Steadfast, IncorporatedInventors: Louis Locatell, Kenneth Norland, F. Donald Roberts, Charles Zepp
-
Patent number: 5149830Abstract: Substituted xanthene compounds are described which are capable of functioning as absorbers in high intensity light protective compositions and in materials used to prevent the transmission of high intensity light at selected wavelengths. Also described are high intensity light protective compositions containing an effective amount of a substituted xanthene compound and a polymeric compound and a material which prevents transmission of high intensity light at wavelengths between about 482 to about 556 nanometers. The material of this invention can be used to make protective eyewear, optical filters, shields for protecting a persons body from high intensity light, or shields for protecting components of an optical instrument from high intensity light.Type: GrantFiled: February 23, 1990Date of Patent: September 22, 1992Assignee: Steadfast, Inc.Inventors: Louis Locatell, Kenneth Norland, F. Donald Roberts, Charles Zepp